Trials / Completed
CompletedNCT01394666
Non-interventional Treatment Patterns Study in Chronic Phase Chronic Myelogenous Leukemia (CP-CML)
Treatment Patterns and Associated Outcomes in Chronic Phase (CP) Chronic Myelogenous Leukemia (CML) Patients Who Fail Imatinib 400 mg Daily
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate treatment patterns and associated outcomes for CP-CML patients who fail Imatinib 400 mg daily in a real-world setting.
Detailed description
Time Perspective: Retrospective and Prospective
Conditions
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2012-12-01
- Completion
- 2012-12-01
- First posted
- 2011-07-14
- Last updated
- 2016-07-11
Source: ClinicalTrials.gov record NCT01394666. Inclusion in this directory is not an endorsement.